Arvinas Holding Company (ARVN) AI Stock Analysis

• Market Cap: $750.14M
• Dividend Yield: N/A
• Average Volume (3M): 2.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 430
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 64,224,300
• 10 Day Avg. Volume: 1,060,233
• 30 Day Avg. Volume: 2,023,299
• PEG Ratio: 0.12
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 5.23
• P/FCF Ratio: -5.28
• Enterprise Value/Market Cap: -0.21
• Enterprise Value/Revenue: -0.49
• Enterprise Value/Gross Profit: -0.49
• Enterprise Value/Ebitda: 1.75
• 1Y Price Target: $13.22
• Price Target Upside: 13.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -0.71
• Revenue Forecast (FY): $289.43M

• Rating: 61 Neutral
• Price Target: $14.00 ▲(19.86% Upside)

Arvinas' overall stock score is driven by its strong technical momentum and positive corporate events, which are tempered by financial challenges and valuation concerns. The promising clinical pipeline and strategic collaborations provide a positive outlook, but ongoing financial and operational challenges remain significant.

Positive Factors

Strong Pipeline Progress

The advancement of multiple clinical programs, including ARV-102 and ARV-806, indicates robust R&D capabilities and potential for future growth.

Financial Stability

A strong cash position ensures operational stability and supports ongoing R&D efforts, enabling the company to sustain its strategic initiatives.

Strategic Collaborations

Partnerships with major pharmaceutical companies like Pfizer enhance resource access and market reach, strengthening Arvinas' competitive position.

Negative Factors

Revenue Decline

A significant revenue drop due to the end of a major agreement highlights dependency on partnerships and potential volatility in financial performance.

Cash Flow Challenges

Ongoing cash flow issues may limit the company's ability to invest in R&D and other strategic initiatives, impacting long-term growth potential.

Delayed Efficacy in Trials

Challenges in achieving desired efficacy in clinical trials could delay product development timelines and affect future revenue streams.

Arvinas Holding Company Business Overview & Revenue Model

Company Description

Arvinas Holding Company (ARVN) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer and other serious diseases through its proprietary protein degradation technology. The company operates primarily in the biopharmaceutical sector, concentrating on the discovery and development of small molecules that harness the body's natural protein disposal system to target and degrade disease-causing proteins. Arvinas aims to address unmet medical needs by creating therapies that have the potential to provide significant clinical benefits over existing treatments.

How the Company Makes Money

Arvinas generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future product sales. The company engages in strategic alliances to co-develop its drug candidates, which allows it to share the financial burden of research and development while also gaining access to additional resources and expertise. Additionally, Arvinas may receive funding from government grants and other non-dilutive sources to support its research initiatives. As its clinical programs advance and potentially lead to new drug approvals, the company aims to monetize these assets through commercialization efforts or further partnerships.

Arvinas Holding Company Financial Statement Overview

Summary

Arvinas is facing significant financial challenges, with declining revenue growth and persistent losses impacting profitability. The balance sheet shows low leverage, which is a positive aspect, but the negative return on equity highlights ongoing difficulties in generating returns. Cash flow issues further compound the financial strain, necessitating strategic adjustments to improve financial health.

Income Statement

Arvinas Holding Company has experienced a decline in revenue growth, with a negative growth rate of -16.23% in the TTM period. The company is facing challenges in profitability, as indicated by negative net profit and EBIT margins. Despite a positive gross profit margin, the overall financial performance is impacted by high operating losses.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.016, indicating low leverage and financial stability. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

Arvinas is experiencing negative free cash flow growth and a high operating cash flow to net income ratio, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is closely aligned with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	312.30M	263.40M	78.50M	131.40M	53.60M	25.90M
Gross Profit	312.30M	263.40M	78.50M	131.40M	53.60M	25.90M
EBITDA	-88.00M	-243.60M	-394.80M	-255.00M	-182.40M	-117.60M
Net Income	-58.50M	-198.90M	-367.30M	-282.50M	-191.00M	-119.30M
Balance Sheet
Total Assets	844.30M	1.09B	1.30B	1.27B	1.58B	717.40M
Cash, Cash Equivalents and Short-Term Investments	787.60M	1.04B	1.26B	1.21B	1.50B	688.60M
Total Debt	9.50M	9.70M	3.20M	5.50M	5.00M	4.10M
Total Liabilities	279.90M	529.70M	644.60M	703.90M	799.90M	75.20M
Stockholders Equity	564.40M	561.70M	660.00M	564.90M	781.70M	642.20M
Cash Flow
Free Cash Flow	-329.50M	-261.10M	-350.70M	-280.30M	554.70M	-96.20M
Operating Cash Flow	-327.50M	-259.30M	-347.80M	-273.50M	559.40M	-89.76M
Investing Cash Flow	360.70M	34.70M	203.50M	242.80M	-1.31B	164.25M
Financing Cash Flow	-16.90M	7.90M	374.70M	4.70M	278.60M	504.67M

Arvinas Holding Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Positive. The current price of 11.68 is below the 20-day moving average (MA) of 12.27, above the 50-day MA of 10.96, and above the 200-day MA of 8.59, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 48.87 is Neutral, neither overbought nor oversold. The STOCH value of 10.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARVN.

Arvinas Holding Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARVN	61 Neutral	$750.14M	-14.54	―	―	―	―
CMPX	60 Neutral	$887.53M	-10.90	-37.82%	―	-100.00%	-28.79%
MGTX	54 Neutral	$646.34M	-3.80	-611.42%	―	96.83%	-61.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	49 Neutral	$1.36B	-17.41	-308.02%	―	196.42%	53.92%
BCAX	48 Neutral	$964.16M	-7.89	-26.64%	―	―	-103.95%
OLMA	46 Neutral	$2.20B	-15.41	-59.22%	―	―	17.23%

Arvinas Holding Company Corporate Events

Arvinas Reveals Promising Preclinical Data for ARV-393

On December 6, 2025, Arvinas, Inc. announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, at the 67th American Society of Hematology Annual Meeting. The data demonstrated that the combination significantly enhanced tumor growth inhibition and increased tumor regression rates in a high-grade B-cell lymphoma model compared to either agent alone. These findings suggest mechanistic synergies between ARV-393 and T-cell engagement, supporting the initiation of a Phase 1 clinical trial in 2026 to explore this combination as a chemotherapy-free treatment for diffuse large B-cell lymphoma.

Arvinas Unveils Promising Preclinical Data for ARV-806

On October 24, 2025, Arvinas, Inc. announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference. The data showed ARV-806’s potential as a best-in-class therapy for KRAS G12D mutated cancers, demonstrating significant potency in degrading KRAS G12D protein and reducing cancer cell proliferation across pancreatic, colorectal, and lung cancer models. The company is currently evaluating ARV-806 in a Phase 1 clinical trial for patients with advanced solid tumors harboring KRAS G12D mutations, highlighting its potential to address high unmet needs in these cancers.

Arvinas Reports Promising Phase 3 Trial Results

On October 20, 2025, Arvinas announced new patient-reported outcomes from its Phase 3 VERITAC-2 clinical trial for vepdegestrant, presented at the ESMO 2025 Congress. Vepdegestrant, developed with Pfizer, showed significant improvements in quality of life and delayed deterioration in patients with ESR1-mutated, ER+/HER2- advanced breast cancer compared to fulvestrant. The trial results reinforce vepdegestrant’s potential as a promising treatment option, highlighting its clinical benefits and supporting its development as a monotherapy for this patient group.

Arvinas Announces Positive Phase 1 Trial Results

On October 5, 2025, Arvinas, Inc. announced positive Phase 1 clinical trial results for ARV-102, a PROTAC LRRK2 degrader, presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trials, conducted on healthy volunteers and Parkinson’s disease patients, demonstrated that ARV-102 was well tolerated and showed dose-dependent increases in cerebrospinal fluid exposure, indicating brain penetration. Significant reductions in LRRK2 protein and pathway biomarkers were observed, supporting further development of ARV-102 for Parkinson’s disease and progressive supranuclear palsy. The company plans to present additional data in 2026 and initiate a Phase 1b trial for progressive supranuclear palsy.

Arvinas Announces 15% Workforce Reduction and Cost Savings

On September 17, 2025, Arvinas announced a 15% workforce reduction primarily affecting roles related to the commercialization of vepdegestrant, expecting to incur $4.5 million in related costs. The company also updated its collaboration with Pfizer, agreeing to out-license vepdegestrant’s commercialization rights to a third party, aiming to optimize costs and streamline operations. Additionally, Arvinas introduced a $100 million share repurchase program, reflecting confidence in its business strength and commitment to maximizing shareholder value. These strategic actions are expected to save over $100 million annually compared to FY 2024 and extend the company’s cash runway into the second half of 2028.